maccura(SZ:300463)2025-04-28 10:50Financial Performance - The company reported a significant decline in performance, with detailed reasons provided in the "Management Discussion and Analysis" section of the annual report[3]. - Maccura Biotechnology reported a revenue of 1.2 billion CNY for the fiscal year 2023, representing a 15% increase compared to the previous year[23]. - The company achieved a net profit of 300 million CNY, which is a 20% growth year-over-year[23]. - The company's operating revenue for 2024 was ¥2,548,756,678.60, a decrease of 11.98% compared to ¥2,895,769,512.02 in 2023[28]. - The net profit attributable to shareholders for 2024 was ¥126,805,274.84, down 59.44% from ¥312,618,556.85 in 2023[28]. - The cash flow from operating activities for 2024 was ¥633,798,557.62, representing a decline of 29.70% from ¥901,510,121.99 in 2023[28]. - The basic earnings per share for 2024 was ¥0.2091, a decrease of 59.29% compared to ¥0.5136 in 2023[28]. - The company reported a net profit of -¥154,567,061.57 in Q4 2024, indicating a significant loss compared to previous quarters[30]. - The company achieved total revenue of 2.55 billion, a year-on-year decrease of 11.98%[82]. - Net profit attributable to shareholders was 127 million, down 59.44% year-on-year, primarily due to goodwill impairment loss of 94 million[79]. Dividend Distribution - The company plans to distribute a cash dividend of 1.04 RMB per 10 shares, based on a total of 608,511,590 shares[12]. - The company plans to distribute a cash dividend of 1.55 RMB per 10 shares, totaling 94,058,297.22 RMB (including tax) based on a share base of 606,827,724 shares[193]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by 2025[23]. - Maccura aims to achieve a revenue target of 1.5 billion CNY for 2024, reflecting a 25% growth forecast[23]. - The company is focusing on enhancing laboratory solutions through a full lifecycle service model, aiming for efficient construction and intelligent operation of laboratories[78]. - The company is actively pursuing market expansion through the introduction of new products and technologies[96]. - The company is committed to enhancing its product offerings in the healthcare sector, particularly in diagnostics[96]. Research and Development - The company is investing in R&D to enhance its core technologies and reduce reliance on imported raw materials, aiming to increase self-sufficiency in key materials[11]. - Maccura has allocated 200 million CNY for R&D in 2024, emphasizing advancements in digital PCR technology[23]. - The company has invested over 16.7 billion yuan in R&D over the past five years, with R&D expenses accounting for 21.91% of self-developed product revenue in the latest reporting period[66]. - The company has completed 75 new R&D projects and filed 582 domestic patents, showcasing its commitment to innovation[67]. - The company has a systematic R&D capability, covering major technical fields such as biochemistry, immunology, and molecular diagnostics[53]. Product Development and Innovation - Maccura plans to launch three new products in the next quarter, focusing on molecular diagnostics and rapid testing technologies[23]. - The company has developed a comprehensive product line covering over 80% of laboratory testing projects, including biochemical, immunological, and molecular diagnostics[50]. - The company has registered 518 in vitro diagnostic products, covering 80% of project needs for various medical institutions[63]. - The company has achieved a self-supply rate of core raw materials of 60% in the last five years, contributing to cost optimization[60]. - The company has registered multiple new products in Colombia, including blood cell analysis reagents and immunoassay kits, further diversifying its market presence[102]. Regulatory Compliance and Risk Management - The company is closely monitoring regulatory changes and adjusting its business strategies accordingly to align with new market rules[4]. - The company acknowledges the risks associated with technological innovation and is enhancing its confidentiality measures to protect core technologies[8]. - The company is facing risks from policy changes in the in vitro diagnostics industry, which may impact operational strategies if not adapted timely[5]. - The implementation of centralized procurement policies is expected to exert downward pressure on product prices across the IVD industry, impacting sales for all companies involved[48]. Governance and Management - The company has a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with corporate governance standards[151]. - The board of directors held 10 meetings during the reporting period, reviewing 37 proposals, which laid a solid foundation for achieving annual goals[153]. - The company has a total of 9 senior management personnel as of the end of the reporting period[170]. - The company has implemented a stock incentive plan for its executives, with specific shares allocated for performance incentives[161]. - The company has a diverse management team with extensive experience in the medical diagnostics industry, ensuring effective leadership[164]. Financial Management - The total cash inflow from operating activities was CNY 3,079,455,479.50, while the total cash outflow was CNY 2,445,656,921.88[115]. - The company has a total of 107,954.3 hours of outsourced labor, with total payments amounting to 3,014,597.50 RMB[192]. - The company has a salary management system that includes basic salary, performance bonuses, year-end bonuses, and other benefits[177]. - The company has not issued any new shares or stock bonuses in the current profit distribution plan, focusing solely on cash dividends[196]. - The company has a total of 0 shares held by independent director Fu Daiguo, with no changes during the period[161].